What is the definition of Gaucher Disease Type 1?

Gaucher disease type 1 (GD1) is the most common form of Gaucher disease. Like other types of Gaucher disease, GD1 is caused when not enough glucocerebrosidase (GBA) is made. GBA is an important enzyme that breaks down a fatty chemical called glucocerebroside. Because the body cannot break down this chemical, fat-filled Gaucher cells build up in areas like the spleen, liver and bone marrow. Unlike type 2 and 3, GD1 does not usually involve the brain and spinal cord (central nervous system). Symptoms of GD1 include enlarged spleen and liver, low blood cell counts, bleeding problems and bone disease. The symptoms can range from mild to severe and may appear anytime from childhood to adulthood. Gaucher disease is caused by changes (mutations) in the GBA gene and is inherited in an autosomal recessive manner. Diagnosis is suspected by clinical symptoms and confirmed by measuring GBA enzyme activity or genetic testing. Treatments may include enzyme replacement therapy or medications that affect the making of fatty molecules (substrate reduction therapy).

What are the alternative names for Gaucher Disease Type 1?

  • Gaucher disease, noncerebral juvenile
  • GD 1
  • Glucocerebrosidase deficiency
  • Acid beta-glucosidase deficiency
  • GBA DEFICIENCY

What are the symptoms for Gaucher Disease Type 1?

Although symptoms of Gaucher disease type 1 (GD1) may vary greatly, the major symptoms include enlargement of the liver and spleen (hepatosplenomegaly), a low number of red blood cells (anemia), easy bruising caused by a decrease in blood platelets (thrombocytopenia), chronic fatigue, lung disease, and bone disease such as bone pain, fractures, and arthritis. People with GD1 may be at in increased risk for Parkinson disease, peripheral neuropathy, certain cancers, and osteoporosis.
  • Condition: Gaucher Disease and GBA-Parkinson Disease
  • Journal: American journal of hematology
  • Treatment Used: Ambroxol
  • Number of Patients: 41
  • Published —
This study evaluated the safety and effectiveness of ambroxol for patients with Gaucher disease (GD) and GBA-Parkinson disease (GBA-PD).
Clinical Trial
  • Status: Recruiting
  • Participants: 200
  • Start Date: June 12, 2017
A Long-term Follow-up Study of Gaucher Disease
Clinical Trial
  • Status: Recruiting
  • Participants: 1257
  • Start Date: July 27, 2010
Gaucher Disease Outcome Survey (GOS)